

One	Corpus-pr edominant	Corpus-pr edominant	4	6	Moderate	None	Mild	None	3	3	3	3	Yes	None	None	Yes	0-II a	antrum	One	Corpus-pr edominant	Corpus-pr edominant	4	6	Moderate	None	Mild	None	3	3	3
Two	Corpus-pr edominant	Corpus-pr edominant	4	5	Severe	None	Mild	None	3	3	2	3	Yes	None	None	Yes	0-II a	antrum	Two	Corpus-pr edominant	Corpus-pr edominant	4	5	Severe	None	Mild	None	3	3	2
One	Pan-atrophy	Pan-atrophy	4	6	Moderate	None	None	None	3	3	3	3	Yes	None	None	Yes	0-II b-II c	corpus	One	Pan-atrophy	Pan-atrophy	4	6	Moderate	None	None	None	3	3	3
One	Corpus-pr edominant	Pan-atrophy	7	8	Moderate	None	Mild	None	3	3	3	4	Yes	None	Yes	Yes	0-II b	corpus	One	Corpus-pr edominant	Pan-atrophy	7	8	Moderate	None	Mild	None	3	3	3

T w o	Corp us-pr edo mina nt	Corp us-pr edo mina nt	5 5	M o de ra te	N o ne	Mild	Non e	3	3	3	3	Y es	N o ne	N o ne	Y es	0-II b	an tr u m	T w o	Corp us-pr edo mina nt	Corp us-pr edo mina nt	5 5	M o de ra te	N o ne	Mild	Non e	3	3	3
O ne	Pan- atrop hy	Pan- atrop hy	5 6	M o de ra te	N o ne	Non e	Non e	3	3	3	3	N o ne	N o ne	Y es	Y es	0-II b-II c	co rp us	O ne	Pan- atrop hy	Pan- atrop hy	5 6	M o de ra te	N o ne	Non e	Non e	3	3	3
O ne	Pan- atrop hy	Pan- atrop hy	5 5	M o de ra te	N o ne	Mod erate	Mild	4	4	4	4	N o ne	N o ne	Y es	Y es	0-II a-II b	an tr u m	O ne	Pan- atrop hy	Pan- atrop hy	5 5	M o de ra te	N o ne	Mod erate	Mild	4	4	4
T w o	Pan- atrop hy	Pan- atrop hy	5 9	Se ve re	N o ne	Mod erate	Non e	3	3	3	3	N o ne	N o ne	N o ne	Y es	0-II a	co rp us	T w o	Pan- atrop hy	Pan- atrop hy	5 9	Se ve re	N o ne	Mod erate	Non e	3	3	3
O ne	Corp us-pr	Pan- atrop	4 6	M o	N o	Non e	Non e	3	3	1	2	N o	N o	N o	Y es	0-II b-II	co rp	O ne	Corp us-pr	Pan- atrop	4 6	M o	N o	Non e	Non e	3	3	1

	edo mina nt	hy			de ra te	ne						ne	ne	ne		c	us		edo mina nt	hy			de ra te	ne						
O ne	Pan- atrop hy	Pan- atrop hy	4	7	Se ve re	M il d	Seve re	Mild	2	2	2	3	N o ne	N o ne	N o ne	Y es	0-II a-II b	an tr u m	O ne	Pan- atrop hy	Pan- atrop hy	4	7	Se ve re	M il d	Seve re	Mild	2	2	2
O ne	Pan- atrop hy	Pan- atrop hy	6	6	M il d	N o ne	Non e	Non e	3	3	2	2	N o ne	N o ne	N o ne	Y es	0-II b	an tr u m	O ne	Pan- atrop hy	Pan- atrop hy	6	6	M il d	N o ne	Non e	Non e	3	3	2
T w o	Antr um	Antr um	5	5	M il d	N o ne	Non e	Non e	2	2	1	2	Y es	N o ne	Y es	Y es	0-II b	an tr u m	T w o	Antr um	Antr um	5	5	M il d	N o ne	Non e	Non e	2	2	1

BMI, Body Mass Index; APCA, anti-Parietal Cell Antibody; AIF, anti-Intrinsic Factor; HP, Helicobacter Pylori; ¹By Kimura and Takemoto; ²By Sydney System; ³According to Paris classification (diameters ranging between 4-14 mm); ⁴Bismuth + Metronidazole + Tetracycline + PPI; ⁵Amoxicillin + Levofloxacin + PPI; ⁶Amoxicillin + Clarithromycin + PPI; EGGIM, Endoscopic

Grading of Gastric Intestinal Metaplasia; MALT, Mucosa-Associated Lymphoid Tissue; OLGA, Operative Link on Gastritis Assessment; OLGIM, Operative Link on Gastric Intestinal Metaplasia; LGD, Low-Grade Dysplasia according to WHO classification; AAG, Autoimmune Atrophic Gastritis.

Supplementary Table 2. Histological characteristics of patients with Low-Grade Dysplasia (LGD) detected on visible gastric lesions or randomly, before and after *Helicobacter pylori* (HP) eradication.

Parameters	Before HP eradication (n = 28)	After HP eradication (n = 28)	P-value
OLGA scale			
Stage 0	0	0	1.0
Stage 1-2	8 (28.6)	7 (25)	0.76
Stage 3-4	20 (71.4)	21 (75)	0.76

OLGIM scale			
Stage 0	0	0	1.0
Stage 1-2	12 (42.8)	7 (25)	0.16
Stage 3-4	16 (57.1)	21 (75)	0.16
Gastritis at histology ¹ , n (%)			
Quiescent	0	26 (92.9)	<0.0001 ^a
Mild	3 (10.7)	2 (7.1)	1.0
Moderate-severe	25 (89.3)	0	<0.0001 ^a
MALT hyperplasia, n (%)			
Absent	10 (35.7)	10 (35.7)	1.0
Mild	10 (35.7)	18 (64.3)	0.03 ^b
Moderate-severe	8 (28.6)	0	0.004 ^a

Data are expressed as number of patients and percentage (in parenthesis); LGD, Low-Grade Dysplasia; *HP*, *Helicobacter pylori*; OLGA, Operative Link on Gastritis Assessment; OLGIM, Operative Link on Gastric Intestinal Metaplasia; ¹By Sydney System; MALT, Mucosa-Associated Lymphoid Tissue; ^aBy Fisher's exact test; ^bBy χ^2 test.

Supplementary Table 3. Histological characteristics of patients without Low-Grade Dysplasia (LGD) before and after *Helicobacter pylori* (*HP*) eradication.

Parameters	Before <i>HP</i> eradication (n = 57)	After <i>HP</i> eradication (n = 57)	<i>P</i> -value
OLGA scale			
Stage 0	4 (7)	4 (7)	1.0
Stage 1-2	48 (84.2)	44 (77.2)	0.76
Stage 3-4	5 (8.8)	9 (15.8)	0.76
OLGIM scale			
Stage 0	40 (70.1)	29 (50.9)	0.03 ^b
Stage 1-2	16 (28.1)	24 (42.1)	0.11
Stage 3-4	1 (1.8)	4 (7)	0.36
Gastritis at histology¹, n (%)			
Quiescent	0	55 (96.5)	<0.0001 ^b
Mild	16 (28.1)	2 (3.5)	0.0005
Moderate-severe	41 (71.9)	0	<0.0001 ^b
MALT hyperplasia, n (%)			
Absent	36 (63.2)	36 (63.2)	1.0
Mild	15 (26.3)	21 (36.8)	0.23 ^b
Moderate-severe	5 (8.8)	0	0.06 ^a

Data are expressed as number of patients and percentage (in parenthesis); LGD, Low-Grade Dysplasia (LGD); *HP*, Helicobacter pylori; OLGA, Operative Link on Gastritis Assessment; OLGIM, Operative Link on Gastric Intestinal Metaplasia; ¹By Sydney System; MALT, Mucosa-Associated Lymphoid Tissue; ^aBy χ^2 test; ^bby Fisher's exact test.